Welcome to LookChem.com Sign In|Join Free


  • or


Post Buying Request

154748-49-9 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

154748-49-9 Usage


Carbamic acid, (3-oxocyclobutyl)-, 1,1-dimethylethyl ester (9CI) is an organic compound with the chemical structure of a carbamic acid ester. It is characterized by a cyclobutyl ring with a carbonyl group and an ester functional group attached to a 1,1-dimethylethyl moiety. Carbamic acid, (3-oxocyclobutyl)-, 1,1-dimethylethyl ester (9CI) is known for its potential applications in the pharmaceutical and chemical industries due to its unique structural features and reactivity.


Used in Pharmaceutical Industry:
Carbamic acid, (3-oxocyclobutyl)-, 1,1-dimethylethyl ester (9CI) is used as a synthetic intermediate for the preparation of 5-HT1-like receptor agonists. These agonists are important in the development of medications targeting various central nervous system disorders, such as migraine, anxiety, and depression.
Used in Antiviral Drug Synthesis:
In the field of antiviral drug development, Carbamic acid, (3-oxocyclobutyl)-, 1,1-dimethylethyl ester (9CI) is utilized to synthesize (oxadiazolyl)quinoline derivatives. These derivatives have been identified as highly potent inhibitors of the Hepatitis C Virus (HCV) NS4B protein, which plays a crucial role in the viral replication process. By targeting this protein, these inhibitors can potentially help in the development of effective treatments for HCV infections.
Used in Chemical Synthesis:
Carbamic acid, (3-oxocyclobutyl)-, 1,1-dimethylethyl ester (9CI) can also be employed as a versatile building block in the synthesis of various organic compounds. Its unique structural features and reactivity make it a valuable component in the development of new molecules with potential applications in various industries, such as agrochemicals, materials science, and specialty chemicals.



Check Digit Verification of cas no

The CAS Registry Mumber 154748-49-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,5,4,7,4 and 8 respectively; the second part has 2 digits, 4 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 154748-49:
159 % 10 = 9
So 154748-49-9 is a valid CAS Registry Number.



According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 10, 2017

Revision Date: Aug 10, 2017


1.1 GHS Product identifier

Product name tert-Butyl 3-oxocyclobutylcarbamate

1.2 Other means of identification

Product number -
Other names 3-(tert-Butoxycarbonylamino)-1-cyclobutanone

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:154748-49-9 SDS

154748-49-9Relevant articles and documents

Preparation method of tert-butyl 3-oxocyclobutyl carbamate


Paragraph 0046-0047, (2020/11/12)

The invention belongs to the technical field of medicines, and particularly relates to a preparation method of tert-butyl 3-oxocyclobutyl carbamate (I). The method comprises the following steps: protecting a compound IV to generate a compound III, carrying out Hofmann degradation reaction to obtain a compound II, and finally, carrying out deprotection to obtain a compound I. Compared with the prior art, the method is low in technical route cost and mild in reaction condition, avoids the use of toxic reagents with larger danger coefficients, is green and environment-friendly, and has good application value.

Novel CDK inhibitory compounds, preparation method thereof, pharmaceutical composition for use in preventing or treating CDK relating diseases containing the same as an active ingredient


Paragraph 0287-0290, (2018/10/24)

The present invention relates to a novel CDK inhibitory compound, a method for manufacturing the same, and a pharmaceutical composition for preventing or treating a CDK-related disease containing the compound as an active ingredient. The novel CDK inhibit



Paragraph 0100, (2017/07/14)

The present disclosure features disclosed method of treating disorders such as COPD, bronchitis and/or asthma using disclosed compounds, optionally together with one or more additional active agents. Contemplated methods include administrating orally or by inhalation to a patient one or more disclosed compounds.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)


What can I do for you?
Get Best Price

Get Best Price for 154748-49-9